Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Participants needed: 780
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Summit TherapeuticsUpdated: Aug 19, 2026Locations: 274
Eligibility criteria

Age ≥ 18 years old at the time of enrollment [+7]

Histologic or cytopathologic evidence of the presence of small cell lung carcino... [+10]

Read more
Status: Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

Participants needed: 600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Summit TherapeuticsUpdated: Aug 4, 2026Locations: 166
Eligibility criteria

ECOG performance status score of 0 or 1 [+4]

Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) dise... [+6]

Read more
Status: Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Participants needed: 1,600
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Summit TherapeuticsUpdated: Apr 30, 2026Locations: 253
Eligibility criteria

Age ≥ 18 years old at the time of enrollment [+7]

Histologic or cytopathologic evidence of the presence of small cell lung carcino... [+4]

Read more